360 related articles for article (PubMed ID: 33788185)
21. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension.
Perros F; Ranchoux B; Izikki M; Bentebbal S; Happé C; Antigny F; Jourdon P; Dorfmüller P; Lecerf F; Fadel E; Simonneau G; Humbert M; Bogaard HJ; Eddahibi S
J Am Coll Cardiol; 2015 Feb; 65(7):668-80. PubMed ID: 25677428
[TBL] [Abstract][Full Text] [Related]
22. Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.
Van der Feen DE; Kurakula K; Tremblay E; Boucherat O; Bossers GPL; Szulcek R; Bourgeois A; Lampron MC; Habbout K; Martineau S; Paulin R; Kulikowski E; Jahagirdar R; Schalij I; Bogaard HJ; Bartelds B; Provencher S; Berger RMF; Bonnet S; Goumans MJ
Am J Respir Crit Care Med; 2019 Oct; 200(7):910-920. PubMed ID: 31042405
[No Abstract] [Full Text] [Related]
23. MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension.
Gomez-Puerto MC; Sun XQ; Schalij I; Orriols M; Pan X; Szulcek R; Goumans MJ; Bogaard HJ; Zhou Q; Ten Dijke P
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32531895
[TBL] [Abstract][Full Text] [Related]
24. Ultrastructural Changes of the Right Ventricular Myocytes in Pulmonary Arterial Hypertension.
Shults NV; Kanovka SS; Ten Eyck JE; Rybka V; Suzuki YJ
J Am Heart Assoc; 2019 Mar; 8(5):e011227. PubMed ID: 30807241
[TBL] [Abstract][Full Text] [Related]
25. Nintedanib improves cardiac fibrosis but leaves pulmonary vascular remodelling unaltered in experimental pulmonary hypertension.
Rol N; de Raaf MA; Sun XQ; Kuiper VP; da Silva Gonçalves Bos D; Happé C; Kurakula K; Dickhoff C; Thuillet R; Tu L; Guignabert C; Schalij I; Lodder K; Pan X; Herrmann FE; van Nieuw Amerongen GP; Koolwijk P; Vonk-Noordegraaf A; de Man FS; Wollin L; Goumans MJ; Szulcek R; Bogaard HJ
Cardiovasc Res; 2019 Feb; 115(2):432-439. PubMed ID: 30032282
[TBL] [Abstract][Full Text] [Related]
26. ADAMTS8 Promotes the Development of Pulmonary Arterial Hypertension and Right Ventricular Failure: A Possible Novel Therapeutic Target.
Omura J; Satoh K; Kikuchi N; Satoh T; Kurosawa R; Nogi M; Ohtsuki T; Al-Mamun ME; Siddique MAH; Yaoita N; Sunamura S; Miyata S; Hoshikawa Y; Okada Y; Shimokawa H
Circ Res; 2019 Oct; 125(10):884-906. PubMed ID: 31556812
[TBL] [Abstract][Full Text] [Related]
27. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
[TBL] [Abstract][Full Text] [Related]
28. Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension.
Vitry G; Paulin R; Grobs Y; Lampron MC; Shimauchi T; Lemay SE; Tremblay E; Habbout K; Awada C; Bourgeois A; Nadeau V; Paradis R; Breuils-Bonnet S; Roux-Dalvai F; Orcholski M; Potus F; Provencher S; Boucherat O; Bonnet S
Am J Respir Crit Care Med; 2021 Mar; 203(5):614-627. PubMed ID: 33021405
[No Abstract] [Full Text] [Related]
29. Galectin-3 Participates in Cardiovascular Remodeling Associated With Obesity.
Martínez-Martínez E; López-Ándres N; Jurado-López R; Rousseau E; Bartolomé MV; Fernández-Celis A; Rossignol P; Islas F; Antequera A; Prieto S; Luaces M; Cachofeiro V
Hypertension; 2015 Nov; 66(5):961-9. PubMed ID: 26351031
[TBL] [Abstract][Full Text] [Related]
30. FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension.
Bourgeois A; Lambert C; Habbout K; Ranchoux B; Paquet-Marceau S; Trinh I; Breuils-Bonnet S; Paradis R; Nadeau V; Paulin R; Provencher S; Bonnet S; Boucherat O
J Mol Med (Berl); 2018 Feb; 96(2):223-235. PubMed ID: 29290032
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effects of mesenchymal stem cell delivery via a novel cardiac bioscaffold on right ventricles of pulmonary arterial hypertensive rats.
Schmuck EG; Hacker TA; Schreier DA; Chesler NC; Wang Z
Am J Physiol Heart Circ Physiol; 2019 May; 316(5):H1005-H1013. PubMed ID: 30822119
[TBL] [Abstract][Full Text] [Related]
32. NMDA-Type Glutamate Receptor Activation Promotes Vascular Remodeling and Pulmonary Arterial Hypertension.
Dumas SJ; Bru-Mercier G; Courboulin A; Quatredeniers M; Rücker-Martin C; Antigny F; Nakhleh MK; Ranchoux B; Gouadon E; Vinhas MC; Vocelle M; Raymond N; Dorfmüller P; Fadel E; Perros F; Humbert M; Cohen-Kaminsky S
Circulation; 2018 May; 137(22):2371-2389. PubMed ID: 29444988
[TBL] [Abstract][Full Text] [Related]
33. Cardiac-deleterious role of galectin-3 in chronic angiotensin II-induced hypertension.
González GE; Rhaleb NE; D'Ambrosio MA; Nakagawa P; Liao TD; Peterson EL; Leung P; Dai X; Janic B; Liu YH; Yang XP; Carretero OA
Am J Physiol Heart Circ Physiol; 2016 Nov; 311(5):H1287-H1296. PubMed ID: 27496875
[TBL] [Abstract][Full Text] [Related]
34. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
35. Signal Mechanisms of Vascular Remodeling in the Development of Pulmonary Arterial Hypertension.
Li MX; Jiang DQ; Wang Y; Chen QZ; Ma YJ; Yu SS; Wang Y
J Cardiovasc Pharmacol; 2016 Feb; 67(2):182-90. PubMed ID: 26448276
[TBL] [Abstract][Full Text] [Related]
36. Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension.
Kurosawa R; Satoh K; Kikuchi N; Kikuchi H; Saigusa D; Al-Mamun ME; Siddique MAH; Omura J; Satoh T; Sunamura S; Nogi M; Numano K; Miyata S; Uruno A; Kano K; Matsumoto Y; Doi T; Aoki J; Oshima Y; Yamamoto M; Shimokawa H
Circ Res; 2019 Jul; 125(3):309-327. PubMed ID: 31195886
[TBL] [Abstract][Full Text] [Related]
37. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene.
Said SI; Hamidi SA; Dickman KG; Szema AM; Lyubsky S; Lin RZ; Jiang YP; Chen JJ; Waschek JA; Kort S
Circulation; 2007 Mar; 115(10):1260-8. PubMed ID: 17309917
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological Inhibition of mTOR Kinase Reverses Right Ventricle Remodeling and Improves Right Ventricle Structure and Function in Rats.
Pena A; Kobir A; Goncharov D; Goda A; Kudryashova TV; Ray A; Vanderpool R; Baust J; Chang B; Mora AL; Gorcsan J; Goncharova EA
Am J Respir Cell Mol Biol; 2017 Nov; 57(5):615-625. PubMed ID: 28679058
[TBL] [Abstract][Full Text] [Related]
39. A critical role for Egr-1 during vascular remodelling in pulmonary arterial hypertension.
Dickinson MG; Kowalski PS; Bartelds B; Borgdorff MA; van der Feen D; Sietsma H; Molema G; Kamps JA; Berger RM
Cardiovasc Res; 2014 Sep; 103(4):573-84. PubMed ID: 25028387
[TBL] [Abstract][Full Text] [Related]
40. Signal Transduction during Metabolic and Inflammatory Reprogramming in Pulmonary Vascular Remodeling.
Gomes MT; Bai Y; Potje SR; Zhang L; Lockett AD; Machado RF
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
